News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,839 Results
Type
Article (41134)
Company Profile (268)
Press Release (680427)
Multimedia
Podcasts (86)
Webinars (17)
Section
Business (204832)
Career Advice (2026)
Deals (35587)
Drug Delivery (111)
Drug Development (81462)
Employer Resources (174)
FDA (16427)
Job Trends (14997)
News (346664)
Policy (32765)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2569)
Accelerated approval (32)
Adcomms (24)
Allergies (139)
Alliances (49619)
ALS (171)
Alzheimer's disease (1664)
Antibody-drug conjugate (ADC) (309)
Approvals (16689)
Artificial intelligence (506)
Autoimmune disease (150)
Automation (37)
Bankruptcy (362)
Best Places to Work (11685)
BIOSECURE Act (20)
Biosimilars (190)
Biotechnology (175)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (633)
Cancer (4776)
Cardiovascular disease (397)
Career advice (1711)
Career pathing (35)
CAR-T (279)
CDC (44)
Celiac Disease (2)
Cell therapy (735)
Cervical cancer (36)
Clinical research (69578)
Collaboration (1686)
Company closure (4)
Compensation (1148)
Complete response letters (54)
COVID-19 (2712)
CRISPR (87)
C-suite (827)
Cystic fibrosis (143)
Data (6178)
Decentralized trials (2)
Denatured (25)
Depression (134)
Diabetes (500)
Diagnostics (6678)
Digital health (45)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (248)
Drug pricing (186)
Drug shortages (28)
Duchenne muscular dystrophy (228)
Earnings (90140)
Editorial (56)
Employer branding (22)
Employer resources (153)
Events (117342)
Executive appointments (966)
FDA (19518)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1456)
Gene editing (192)
Generative AI (43)
Gene therapy (591)
GLP-1 (970)
Government (4671)
Grass and pollen (6)
Guidances (383)
Healthcare (18871)
HIV (56)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (252)
Immuno-oncology (56)
Indications (104)
Infectious disease (2972)
Inflammatory bowel disease (188)
Inflation Reduction Act (14)
Influenza (111)
Intellectual property (242)
Interviews (315)
IPO (16655)
IRA (49)
Job creations (3653)
Job search strategy (1431)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (548)
Leadership (30)
Legal (7961)
Liver cancer (91)
Longevity (14)
Lung cancer (645)
Lymphoma (375)
Machine learning (42)
Management (59)
Manufacturing (784)
MASH (161)
Medical device (13757)
Medtech (13809)
Mergers & acquisitions (19996)
Metabolic disorders (1262)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (318)
Neuropsychiatric disorders (88)
Neuroscience (2890)
Neurotech (1)
NextGen: Class of 2026 (6528)
Non-profit (4513)
Now hiring (66)
Obesity (592)
Opinion (258)
Ovarian cancer (166)
Pain (197)
Pancreatic cancer (223)
Parkinson's disease (283)
Partnered (33)
Patents (491)
Patient recruitment (477)
Peanut (55)
People (58860)
Pharmaceutical (62)
Pharmacy benefit managers (30)
Phase 1 (21691)
Phase 2 (30628)
Phase 3 (22829)
Pipeline (5160)
Policy (281)
Postmarket research (2565)
Preclinical (9196)
Press Release (64)
Prostate cancer (235)
Psychedelics (48)
Radiopharmaceuticals (278)
Rare diseases (824)
Real estate (5962)
Recruiting (71)
Regulatory (24462)
Reports (51)
Research institute (2388)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (17)
RSV (76)
Schizophrenia (148)
Series A (239)
Series B (191)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3617)
State (2)
Stomach cancer (17)
Supply chain (105)
Tariffs (89)
The Weekly (59)
Vaccines (991)
Venture capital (86)
Weight loss (381)
Women's health (89)
Worklife (18)
Date
Today (138)
Last 7 days (622)
Last 30 days (2172)
Last 365 days (29892)
2026 (3047)
2025 (30213)
2024 (35256)
2023 (40117)
2022 (51214)
2021 (55748)
2020 (54105)
2019 (46582)
2018 (35071)
2017 (32159)
2016 (31521)
2015 (37586)
2014 (31363)
2013 (26367)
2012 (28578)
2011 (29263)
2010 (27328)
Location
Africa (739)
Alabama (83)
Alaska (7)
Arizona (306)
Arkansas (13)
Asia (39224)
Australia (6409)
California (11196)
Canada (3263)
China (1093)
Colorado (474)
Connecticut (471)
Delaware (333)
Europe (84567)
Florida (1668)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (867)
India (64)
Indiana (516)
Iowa (22)
Japan (422)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1371)
Massachusetts (8032)
Michigan (320)
Minnesota (622)
Mississippi (5)
Missouri (127)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2975)
New Mexico (28)
New York (2953)
North Carolina (1443)
North Dakota (8)
Northern California (5461)
Ohio (331)
Oklahoma (21)
Oregon (41)
Pennsylvania (2262)
Puerto Rico (23)
Rhode Island (47)
South America (1111)
South Carolina (65)
South Dakota (1)
Southern California (4357)
Tennessee (175)
Texas (1728)
United States (39715)
Utah (334)
Vermont (1)
Virginia (258)
Washington D.C. (81)
Washington State (914)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
721,839 Results for "abbvie inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
February 4, 2026
·
2 min read
·
Dan Samorodnitsky
Psychedelics
AbbVie CSO Touts ‘Breakthrough Type Therapy’ Psychedelic as J&J’s Spravato Keeps Growing
Sales of Johnson & Johnson’s esketamine-based nasal spray jumped in the fourth quarter last year, priming the pump for a suite of other pharmas, including AbbVie, champing at the bit with their own psychedelics.
February 6, 2026
·
2 min read
·
Dan Samorodnitsky
Manufacturing
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions
AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient basis. In exchange, the pharma secured exemptions from tariffs and other future pricing directives.
January 13, 2026
·
2 min read
·
Tristan Manalac
Cancer
AbbVie Bets Nearly $5B on RemeGen To Vie for Position in Hot Bispecific Market
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Cancer
JPM26: AbbVie Seeks Respect for Oncology Pipeline Following RemeGen Buy
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
January 14, 2026
·
2 min read
·
Heather McKenzie
Layoffs
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial for amyotrophic lateral sclerosis.
November 13, 2025
·
2 min read
·
Tristan Manalac
Earnings
AbbVie’s Immunology Dyad Dominates Again in Q3
Skyrizi and Rinvoq made nearly $7 billion combined, almost half of the company’s income for the quarter alone.
October 31, 2025
·
2 min read
·
Dan Samorodnitsky
Psychedelics
Psychedelics Space Enters New Era as AbbVie Dives In
With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval.
September 22, 2025
·
6 min read
·
Heather McKenzie
Press Releases
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
February 5, 2026
·
25 min read
1 of 72,184
Next
